



07-13-05

\$ IFW

Express Mail No. ED 884 288 991 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant of: Robert J. Hariri

Confirmation No.: 2020

Serial No.: 10/779,369

Art Unit: 1651

Filed: February 13, 2004

Examiner: Lora Elizabeth Barnhart

For: USE OF UMBILICAL CORD
BLOOD TO TREAT INDIVIDUALS
HAVING A DISEASE, DISORDER
OR CONDITION

Attorney Docket No: 9516-141-999
(CAM:) (501872-999140)

FEE TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit a fee of \$180 in accordance with 37 C.F.R.1.97(c) in conjunction with the attached Supplemental Information Disclosure Statement. Please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is attached for accounting purposes.

Respectfully submitted,

Date: July 11, 2005

U. Britva
By: Irina E. Britva, Ph.D. Patent Agent Reg. No. 50,498
For: Anthony M. Insogna, Esq. Reg. No. 35,203

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

BEST AVAILABLE COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Robert J. Hariri

Confirmation No.: 2020

Serial No.: 10,779,369

Art Unit: 1651

Filed: February 13, 2004

Examiner: Lora Elizabeth Barnhart

For: USE OF UMBILICAL CORD BLOOD TO
TREAT INDIVIDUALS HAVING A
DISEASE, DISORDER OR CONDITION

Attorney Docket No.: 9516-141-999
(CAM:) (501872-999140)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:

1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.

1b. A legible copy of:

☒ Each U.S. patent, US patent application publication and foreign patent. Pursuant to 37 CFR 1.98(a)(2) as amended (Federal Register, vol. 69, No.182, September 21, 2004, p.56510), copies of U.S. patents and US patent application publications are not submitted herewith;

☒ Each publication or that portion which caused it to be listed on the PTO-1449;

☒ For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;

☒ all other information or portion which caused it to be listed on the PTO-1449.

1c. ☐ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.

1d. ☐ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.

2. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):

☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);

07/14/2005 SSITHIB1 00000041 503013 10779369

01 FC:1806 180.00 DA

- ☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
- ☐ Before the mailing of the first Office action on the merits;
- ☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

(Check either Item 3a or 3b)

- 3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. ☒ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
☐ enclosed
☒ to be charged to Jones Day Deposit Account No. 50-3013.

(Item 3b to be checked if any reference known for more than 3 months)

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The Certification Statement in Item 5 below is applicable.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- ☐ enclosed.
☐ to be charged to Jones Day Deposit Account No. 50-3013

5. ☐ Certification Statement (applicable if Item 3a or Item 4 is checked)

(Check either Item 5a or 5b)


- 5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- 5b. ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 5c. ☐ Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
6. ☐ This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).

(Check appropriate Items 6a, 6b and/or 6c)

- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 6b. ☐ Copies of publications listed on Form PTO-1449 from prior application Serial No. _____, filed on _____, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c. ☐ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. _____, filed on _____, and are provided herewith.
7. ☒ This is a Supplemental Information Disclosure Statement.
- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on _____. A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on _____.
8. ☐ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:
- (Check Item 8a, 8b, or 8c)
- 8a. ☐ satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b. ☐ set forth in the application.
- 8c. ☐ enclosed as an attachment hereto.
9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 50-3013.
10. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: July 11, 2005

By: 
For: Irina E. Britva, Ph.D., Patent Agent
Anthony M. Insogna

Reg. No. 50,498
Reg. No. 35,203

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.
9516-141-999
(501872-999140)

APPLICATION NO

10/779,369

APPLICANT
HARIRI, Robert J.

CONFIRMATION NO.:

2020

FILING DATE
February 13, 2004

ART UNIT:

1651



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A36	US 2002/0123141		Hariri, Robert J.			12/5/2001
	A37	US 2002/0132343		Lum			03/06/2002
	A38	US 2002/0160510		Hariri, Robert J.			02/13/2002
	A39	US 2004/0171147		Hariri, Robert J.			11/25/2003
	A40	3,862,002	01/21/75	Sanders			
	A41	5,197,985	3/30/93	Caplan et al.			
	A42	5,226,914	7/13/93	Caplan et al.			
	A43	5,272,071	12/21/93	Chappel			
	A44	5,460,964	10/24/95	McGlave et al.			
	A45	5,464,764	11/7/95	Capecchi et al.			
	A46	5,486,359	1/23/96	Caplan et al.			
	A47	5,487,992	11/7/95	Capecchi et al.			
	A48	5,516,532	5/14/96	Atala et al.			
	A49	5,591,625	1/7/97	Gerson et al.			
	A50	5,605,822	2/25/97	Emerson et al.			
	A51	5,627,059	5/6/97	Capecchi et al.			
	A52	5,635,386	6/3/97	Palsson et al.			
	A53	5,635,387	6/3/97	Fei et al.			
	A54	5,643,741	6/1/97	Tsukamoto et al.			
	A55	5,654,381	8/5/97	Hrkach et al.			
	A56	5,668,104	9/16/97	Nakahata et al.			
	A57	5,672,346	9/30/97	Srour et al.			
	A58	5,709,854	1/20/98	Griffith-Cima et al.			
	A59	5,716,616	2/10/98	Prockop et al.			
	A60	5,716,794	2/10/98	Tjota et al.			
	A61	5,733,542	3/31/98	Haynesworth et al.			
	A62	5,744,361	4/28/98	Hoffman et al.			
	A63	5,763,197	6/9/98	Tsukamoto et al.			
	A64	5,807,686	9/15/98	Wagner et al.			
	A65	5,811,094	9/22/98	Caplan et al.			
	A66	5,827,735	10/27/98	Young et al.			
	A67	5,827,740	10/27/98	Pittenger			
	A68	5,837,539	11/17/98	Caplan et al.			
	A69	5,849,553	12/15/98	Anderson et al.			
	A70	5,851,984	12/22/98	Matthews et al.			

	A71	5,858,782	1/12/99	Long et al.			
	A72	5,877,299	6/2/99	Thomas et al.			
	A73	5,879,318	3/9/99	Van Der Heiden et al.			
	A74	5,879,940	3/9/99	Torok-Storb et al.			
	A75	5,905,041	5/18/99	Beug et al.			
	A76	5,906,934	5/25/99	Grande et al.			
	A77	5,908,782	6/1/99	Marshak et al.			
	A78	5,908,784	6/1/99	Johnstone et al.			
	A79	5,914,108	6/22/99	Tsukamoto et al.			
	A80	5,914,268	6/22/99	Keller et al.			
	A81	5,916,202	6/29/99	Haswell			
	A82	5,919,176	7/6/99	Kuypers et al.			
	A83	5,922,597	7/13/99	Varfaille et al.			
	A84	5,925,567	7/20/99	Kraus et al.			
	A85	5,928,214	07/1999	Rubinstein et al.			
	A86	5,928,947	7/27/99	Kuypers et al.			
	A87	5,942,225	8/24/99	Bruder et al.			
	A88	5,942,496	8/24/99	Bonadio et al.			
	A89	5,958,767	9/28/99	Snyder et al.			
	A90	5,962,325	10/5/99	Naughton et al.			
	A91	5,968,829	10/19/99	Carpenter			
	A92	5,969,105	10/19/99	Feng et al.			
	A93	5,993,429	11/30/99	Kuypers, et al.			
	A94	5,997,860	12/7/97	Brauer et al.			
	A95	6,001,654	12/14/00	Anderson et al.			
	A96	6,010,696	¼/00	Caplan et al.			
	A97	6,011,000	¼/ 00	Faller et al.			
	A98	6,020,469	2/1/00	Hershenson			
	A99	6,022,743	2/8/00	Naughton et al.			
	A65	6,022,848	2/8/00	Kozlov et al.			
	A100	6,057,123	5/2/00	Craig et al.			
	A101	6,059,968	05/2000	Wolf, Jr.			
	A102	6,077,708	6/20/00	Collins et al.			
	A103	6,087,113	7/11/00	Caplan et al.			
	A104	6,093,531	7/25/00	Bjornson et al.			
	A105	6,127,135	10/3/00	Hill et al.			
	A106	6,146,888	11/14/00	Smith et al.			
	A107	6,184,035 B1	2/6/01	Csete et al.			
	A108	6,190,368 B1	2/20/01	Kuypers et al.			
	A109	6,214,369 B1	4/10/01	Grande et al.			
	A110	6,227,202 B1	5/8/01	Mataparkar			
	A111	6,231,880 B1	5/15/01	Perrine			
	A112	6,248,587 B1	6/19/01	Rodgers et al.			
	A113	6,251,383 B1	6/26/01	Upadhyay et al.			
	A114	6,255,112 B1	7/3/01	Thiede et al.			

	A115	6,261,549 B1	7/17/01	Fernandez et al.			
	A116	6,300,314 B1	10/9/01	Wallner et al.			
	A117	6,312,950 B1	11/6/01	Ohmura et al.			
	A118	6,322,784 B1	11/27/01	Pittenger et al.			
	A119	6,328,765 B1	12/11/01	Hardwick et al.			
	A120	6,338,942 B2	1/15/02	Kraus et al.			
	A121	6,461,645	10/08/02	Boyse et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B2	WO 90/11354 A1	10/4/90	PCT				
	B3	WO 91/01140 A1	2/7/91	PCT				
	B4	WO 91/06667 A1	5/16/91	PCT				
	B5	WO 93/04169 A1	3/4/93	PCT				
	B6	WO 95/22611 A2&A3	8/24/95	PCT				
	B7	WO 96/34035 A2&A3	10/31/96	PCT				
	B8	WO 96/39101 A1	12/12/96	PCT				
	B9	WO 98/37903 A1	9/3/98	PCT				
	B10	WO 00/17325 A1	3/30/00	PCT				
	B11	WO 00/27999 A2&A3	5/18/00	PCT				
	B12	WO 00/73421 A2&A3	12/7/00	PCT				
	B13	WO 01/93909 A2&A3	12/12/01	PCT				
	B14	WO 01/21767	03/29/01	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C23	Abkowitz, 2002, Can human hematopoietic stem cells become skin, gut, or liver cells? N Engl J Med. 346(10):770-2.
	C24	Addison et al., "Metabolism of Prednisolone by the Isolated Perfused Human Placental Lobule", J. Ster. Biochem Mol. Biol., Vol. 39 No. 1, pp. 83-90 (1991).
	C25	Barry, 1994, "Where do all the placentas go?" Canadian Journal of Infection Control 9(1):8-10.
	C26	Belvedere et al., 2000, "Increased blood volume and CD34(+)CD38(-) progenitor cell recovery using a novel umbilical cord blood collection system," Stem Cells 18(4):245-251.
	C27	Caplan, "The Mesengenic Process," Clin. Plast. Surg. 21(3):429-435 (1994).
	C28	CD34, Medline Mesh Database, 2004.
	C29	Cole et al., 1985, EBV-Hydradoma technique and its application to human lung cancer. <i>In Monoclonal Antibodies and Cancer Therapy</i> , Alan R. Liss, Inc., 77-96.
	C30	Contractor et al., 1984, "A comparison of the effects of different perfusion regimens on the structure of the isolated human placental lobule," Cell Tissue Res. 237:609-617
	C31	Cord Blood Stem Cell, Mesh Term Database 2003.
	C32	Cote et al., 1983, Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci U S A. 80(7):2026-30.
	C33	Czarneski, J. et al., 1999, "Effects of Cord Blood Transfer on the Hematopoietic Recovery Following Sublethal Irradiation in MRL lpr/lpr Mice," Proc. Soc. Exp. Biol. Med. 220(2):79-87
	C34	Damjanov et al., 1993, Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. Lab Invest. 68(2):220-32.
	C35	DeLoia et al, 1998, Effects of methotrexate on trophoblast proliferation and local immune responses. Hum Reprod. 13(4):1063-9.
	C36	Dorrel, 2000, Expansion of human cord blood CD34+CD38- cells in <i>ex vivo</i> culture during retroviral transduction without a corresponding increase in SCID repopulation cell (SRC) frequency: dissociation of SRC phenotype and function, Blood, 95(1):102-110.
	C37	Douay et al, 1995. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide. Bone Marrow Transplant. 15(5):769-75.

C38	Dushnik-Levinson et al. 1995, Embryogenesis in vitro: study of differentiation of embryonic stem cells. <i>Biol Neonate</i> . 67(2):77-83.
C39	Elchalal et al., 2000, "Postpartum umbilical cord blood collection for transplantation: a comparison of three methods," <i>Am. J. of Obstetrics & Gyn.</i> 182(1 Pt 1):227-232
C40	Emerson, 1996, Ex vivo expansion of hematopoietic precursors, progenitors and stem cells. The next generation of cellular therapeutics, <i>Blood</i> 87(8):3082-3088.
C41	Ende, N. et al., 1995, "The Effect of Human Cord Blood on SJL/J Mice After Chemoablation and Irradiation and Its Possible Clinical Significance," <i>Immunol. Invest.</i> 24(6):999-1012
C42	Genbacev et al. 1995, Maternal smoking inhibits early human cytotrophoblast differentiation. <i>Reprod Toxicol.</i> 9(3):245-55.
C43	Hatzopoulos et al. 1998, Isolation and characterization of endothelial progenitor cells from mouse embryos. <i>Development.</i> 125(8):1457-68.
C44	Himori, et al. 1984, Chemotherapeutic susceptibility of human bone marrow progenitor cells and human myelogenous leukemia cells (HL-60) in co-culture: preliminary report. <i>Int J Cell Cloning.</i> 2(4):254-62.
C45	Hirashima et al. 1999, Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis. <i>Blood.</i> 93(4):1253-63.
C46	Keown et al., 1990, Methods for introducing DNA into mammalian cells. <i>Methods Enzymol.</i> 185:527-37.
C47	Korbling et al., 2002, Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. <i>N Engl J Med.</i> 346(10):738-46.
C48	Kozbor et al., 1983, The production of monoclonal antibodies from human lymphocytes. <i>Immunology Today</i> 4, 72-79
C49	Kurtzberg et al., 1996, <i>New Eng J Med</i> 335:157-166.
C50	Larsson et al., 2002, <i>Angiogenesis</i> 5,107-110.
C51	Lowy et al. 1980, Isolation of transforming DNA: cloning the hamster apt gene. <i>Cell.</i> 22(3):817-23.
C52	Ma et al., 1999, <i>Tissue Engineering</i> 5:91-102.
C53	Melchner, et al., 1985, Human placental conditioned medium reverses apparent commitment to differentiation of human promyelocytic leukemia cells (HL60). <i>Blood.</i> 66(6):1469-72.
C54	Minguel et al., 2001, <i>Exp Biol Med</i> 226:507-520.
C55	Moore et al., 1997, "A simple perfusion technique for isolation of maternal intervillous blood mononuclear cells from human placentae," <i>J. Immunol. Methods</i> 209(1):93-104
C56	Muhlemann et al., 1995, <i>Placenta</i> 16:367-373.
C57	Mulligan and Berg, 1981 Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase <i>Proc Natl Acad Sci U S A.</i> 78(4):2072-6.
C58	Myllynen, "In Search of Models for Hepatic and Placental Pharmacokinetics, dissertation, University of Oulu (2003)
C59	Nadkarni et al. 1984, Effect of retinoic acid on bone-marrow committed stem cells (CFU-c) from chronic myeloid leukemia patients. <i>Tumori.</i> 70(6):503-5.
C60	O'Hare et al. 1981, Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase. <i>Proc Natl Acad Sci U S A.</i> 78(3):1527-31.
C61	Ordi et al., 1998, <i>Am J Surg Pathol</i> 8:1006-1011.
C62	Papaioannou et al., <i>Stem Cell Handbook</i> 2004, 19-31.
C63	Placenta, <i>Encyclopedia Britannica</i> , 2003.
C64	Ray et al., 1997, CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. <i>J Biol Chem.</i> 1997 Jul 25;272(30):18702-8.
C65	Reyes et al. 2002, Origin of endothelial progenitors in human postnatal bone marrow. <i>J Clin Invest.</i> 109(3):337-46.
C66	Santerre et al., 1984, Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells. <i>Gene.</i> 30(1-3):147-56.
C67	Shamblott, et al., 1998, Derivation of pluripotent stem cells from cultured human primordial germ cells. <i>Proc Natl Acad Sci U S A.</i> 95(23):13726-31.
C68	Slager 1993, Transforming growth factor-beta in the early mouse embryo: implications for the regulation of muscle formation and implantation. <i>Dev Genet.</i> 14(3):212-24.
C69	Smithies et al. 1985, Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. <i>Nature.</i> 317(6034):230-4.
C70	Srour, 1999, Ex vivo expansion of hematopoietic stem and progenitor cells. Are we there yet? <i>The Journal of Hematotherapy</i> 8:93-102.
C71	Szybalska and Szybalska, 1962, Genetics of human cell lines IV: DNA-mediated heritable transformation of a biochemical trait. <i>PNAS</i> 48: 2026-2034
C72	Thomas and Capecchi, 1987, Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. <i>Cell.</i> 51(3):503-12.

C73	Thomson et al., 1998, Embryonic stem cell lines derived from human blastocysts. Science. 282 (5391): 1145-7.
C74	Totipotent stem cells, Stem Cells Information Center On-line, 2004.
C75	Totipotent stem cells, Medline Mesh Database, 2004.
C76	Tremblay et al., 2001, Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERR beta. Genes Dev. 15(7):833-8.
C77	Turner et al., 1992, "A modified harvest technique for cord blood hematopoietic stem cells," Bone Marrow Transplantation 10:89-91
C78	Uchimura et al. 1998, Human N-acetylglucosamine-6-O-sulfotransferase involved in the biosynthesis of 6-sulfo sialyl Lewis X: molecular cloning, chromosomal mapping, and expression in various organs and tumor cells. J Biochem (Tokyo). 124(3):670-8.
C79	Van Bakkum, "The Pluripotent Hemopoietic Stem Cell: Its Identification and Applications," <i>Verh. Dtsch. Ges. Pathol.</i> 74:19-24 (1990)
C80	Wang et al., 2001, "Enhanced recovery of hematopoietic progenitor and stem cells from cultivated, postpartum human placenta," Blood 98(11/1):183a Abstract no. 769
C81	Wigler et al. 1997, Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell. 11(1):223-32.
C82	Yan et al., 2001, Retinoic acid promotes differentiation of trophoblast stem cells to a giant cell fate. Dev Biol. 235(2):422-32.
C83	Ye et al., 2001, "Recovery of placental-derived adherent cells with mesenchymal stem cell characteristics," Blood 98(11/1):147b Abstract no. 4260

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	